This is a routine insider onboarding filing with no trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Fuchs, which would provide actionable insider sentiment.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $17.86entry
- T+1 · 3mo ago +2.91%α +3.11% · $18.38
- T+5 · 3mo ago −4.37%α −2.40% · $17.08
- T+20 · 2mo ago −11.09%α −9.34% · $15.88
- T+60 · 11d ago −19.32%α −13.84% · $14.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Charles S. Fuchs, President of R&D at Erasca, filed a Form 3 initial statement of beneficial ownership, indicating he became a reporting insider. This is a routine administrative filing with no trading activity or financial details disclosed, and carries no material stock-moving implications.
Key Facts
- Charles S. Fuchs filed a Form 3 initial statement of beneficial ownership on 2026-08-10.
- Fuchs serves as President, R&D at Erasca, Inc.
- The filing is a standard SEC requirement for new insiders and contains no trading or financial data.
Financial Impact
No financial impact, filing contains no monetary figures or transaction details.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-346920 |
| Document: 0001193125-26-346920-index.html | 0001193125-26-346920 |
| Document: 0001193125-26-346920.txt | 0001193125-26-346920 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Viewing Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers